These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 19627169)

  • 21. Two decades of pegfilgrastim: what have we learned? Where do we go from here?
    De Oliveira Brandao C; Lewis S; Sandschafer D; Crawford J
    Curr Med Res Opin; 2023 May; 39(5):707-718. PubMed ID: 36976784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.
    Lyman GH; Lalla A; Barron RL; Dubois RW
    Clin Ther; 2009 May; 31(5):1092-104. PubMed ID: 19539110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegfilgrastim -- rational drug design for the management of chemotherapy-induced neutropenia.
    Lüftner D; Possinger K
    Onkologie; 2005 Nov; 28(11):595-602. PubMed ID: 16249646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
    Pfeil AM; Allcott K; Pettengell R; von Minckwitz G; Schwenkglenks M; Szabo Z
    Support Care Cancer; 2015 Feb; 23(2):525-45. PubMed ID: 25284721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.
    Crawford J
    Pharmacotherapy; 2003 Aug; 23(8 Pt 2):15S-19S. PubMed ID: 12921218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pegfilgrastim use during chemotherapy: current and future applications.
    Wolf T; Densmore JJ
    Curr Hematol Rep; 2004 Nov; 3(6):419-23. PubMed ID: 15496275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.
    Crawford J
    Drugs; 2002; 62 Suppl 1():89-98. PubMed ID: 12479597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia.
    Crawford J
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):22-8. PubMed ID: 16736985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.
    Waladkhani AR
    Eur J Cancer Care (Engl); 2004 Sep; 13(4):371-9. PubMed ID: 15305906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
    Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
    Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia.
    Aapro M; Cornes P; Abraham I
    J Oncol Pharm Pract; 2012 Jun; 18(2):171-9. PubMed ID: 21610020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pegfilgrastim.
    Willis F; Pettengell R
    Expert Opin Biol Ther; 2002 Dec; 2(8):985-92. PubMed ID: 12517276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
    Milano-Bausset E; Gaudart J; Rome A; Coze C; Gentet JC; Padovani L; Lacarelle B; André N
    Clin Ther; 2009; 31 Pt 2():2388-95. PubMed ID: 20110048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta).
    Molineux G
    Curr Pharm Des; 2004; 10(11):1235-44. PubMed ID: 15078138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
    Mahtani R; Crawford J; Flannery SM; Lawrence T; Schenfeld J; Gawade PL
    BMC Cancer; 2021 May; 21(1):621. PubMed ID: 34044798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [OPERa Study].
    Tesařová P
    Klin Onkol; 2013; 26(6):425-33. PubMed ID: 24320592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients.
    Molineux G
    Anticancer Drugs; 2003 Apr; 14(4):259-64. PubMed ID: 12679729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
    Lathia N; Isogai PK; De Angelis C; Smith TJ; Cheung M; Mittmann N; Hoch JS; Walker S
    J Natl Cancer Inst; 2013 Aug; 105(15):1078-85. PubMed ID: 23873405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy.
    André N; Kababri ME; Bertrand P; Rome A; Coze C; Gentet JC; Bernard JL
    Anticancer Drugs; 2007 Mar; 18(3):277-81. PubMed ID: 17264759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy.
    Lyman GH; Reiner M; Morrow PK; Crawford J
    Ann Oncol; 2015 Jul; 26(7):1452-8. PubMed ID: 25851633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.